nodes	percent_of_prediction	percent_of_DWPC	metapath
Labetalol—hypertension—adrenal gland cancer	0.972	1	CtDrD
Labetalol—ADRB3—brown adipose tissue—adrenal gland cancer	0.0156	0.849	CbGeAlD
Labetalol—CYP2D6—urine—adrenal gland cancer	0.00188	0.102	CbGeAlD
Labetalol—ADRB1—cardiac atrium—adrenal gland cancer	0.000886	0.0482	CbGeAlD
Labetalol—Mirabegron—ABCB1—adrenal gland cancer	0.00053	0.258	CrCbGaD
Labetalol—Salsalate—PTGS2—adrenal gland cancer	0.00045	0.22	CrCbGaD
Labetalol—Fenoprofen—PTGS2—adrenal gland cancer	0.000372	0.181	CrCbGaD
Labetalol—ADRB3—Calcium Regulation in the Cardiac Cell—KCNJ5—adrenal gland cancer	0.000318	0.0454	CbGpPWpGaD
Labetalol—ADRB2—Arf6 signaling events—TSHR—adrenal gland cancer	0.000314	0.0449	CbGpPWpGaD
Labetalol—CYP2D6—Codeine and Morphine Metabolism—ABCB1—adrenal gland cancer	0.000293	0.0418	CbGpPWpGaD
Labetalol—ADRB2—GPCRs, Other—GNRHR—adrenal gland cancer	0.000274	0.0391	CbGpPWpGaD
Labetalol—ADRB2—Arf6 trafficking events—TSHR—adrenal gland cancer	0.000248	0.0355	CbGpPWpGaD
Labetalol—Flurbiprofen—PTGS2—adrenal gland cancer	0.000243	0.118	CrCbGaD
Labetalol—Propafenone—ABCB1—adrenal gland cancer	0.000237	0.115	CrCbGaD
Labetalol—Ketoprofen—PTGS2—adrenal gland cancer	0.00022	0.107	CrCbGaD
Labetalol—ADRB3—G alpha (s) signalling events—TSHR—adrenal gland cancer	0.000197	0.0281	CbGpPWpGaD
Labetalol—ADRB1—Endothelin Pathways—GNAS—adrenal gland cancer	0.000196	0.028	CbGpPWpGaD
Labetalol—ADRB1—Calcium Regulation in the Cardiac Cell—KCNJ5—adrenal gland cancer	0.000189	0.027	CbGpPWpGaD
Labetalol—ADRB2—Calcium Regulation in the Cardiac Cell—KCNJ5—adrenal gland cancer	0.000185	0.0264	CbGpPWpGaD
Labetalol—ADRB3—Class A/1 (Rhodopsin-like receptors)—GNRHR—adrenal gland cancer	0.000176	0.0251	CbGpPWpGaD
Labetalol—ADRB3—GPCR ligand binding—GNRHR—adrenal gland cancer	0.000134	0.0191	CbGpPWpGaD
Labetalol—ADRB3—Calcium Regulation in the Cardiac Cell—PRKACA—adrenal gland cancer	0.000122	0.0174	CbGpPWpGaD
Labetalol—ADRB1—G alpha (s) signalling events—TSHR—adrenal gland cancer	0.000117	0.0167	CbGpPWpGaD
Labetalol—ADRB3—G alpha (s) signalling events—GNAS—adrenal gland cancer	0.000115	0.0163	CbGpPWpGaD
Labetalol—ADRB2—G alpha (s) signalling events—TSHR—adrenal gland cancer	0.000114	0.0163	CbGpPWpGaD
Labetalol—ADRB3—Class A/1 (Rhodopsin-like receptors)—GNRH1—adrenal gland cancer	0.000105	0.015	CbGpPWpGaD
Labetalol—ADRB1—Class A/1 (Rhodopsin-like receptors)—GNRHR—adrenal gland cancer	0.000104	0.0149	CbGpPWpGaD
Labetalol—ADRB2—Class A/1 (Rhodopsin-like receptors)—GNRHR—adrenal gland cancer	0.000102	0.0146	CbGpPWpGaD
Labetalol—ADRB3—Calcium Regulation in the Cardiac Cell—GNAS—adrenal gland cancer	9.89e-05	0.0141	CbGpPWpGaD
Labetalol—ADRB3—Class A/1 (Rhodopsin-like receptors)—TSHR—adrenal gland cancer	9.39e-05	0.0134	CbGpPWpGaD
Labetalol—ADRB3—GPCR ligand binding—GNRH1—adrenal gland cancer	8.02e-05	0.0114	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—GNRHR—adrenal gland cancer	7.95e-05	0.0113	CbGpPWpGaD
Labetalol—ADRB2—GPCR ligand binding—GNRHR—adrenal gland cancer	7.77e-05	0.0111	CbGpPWpGaD
Labetalol—ADRB3—G alpha (s) signalling events—POMC—adrenal gland cancer	7.71e-05	0.011	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—GNRHR—adrenal gland cancer	7.56e-05	0.0108	CbGpPWpGaD
Labetalol—ADRB1—Calcium Regulation in the Cardiac Cell—PRKACA—adrenal gland cancer	7.24e-05	0.0103	CbGpPWpGaD
Labetalol—ADRB3—GPCR ligand binding—TSHR—adrenal gland cancer	7.15e-05	0.0102	CbGpPWpGaD
Labetalol—ADRB2—Calcium Regulation in the Cardiac Cell—PRKACA—adrenal gland cancer	7.08e-05	0.0101	CbGpPWpGaD
Labetalol—ADRB2—Arf6 signaling events—EGFR—adrenal gland cancer	6.96e-05	0.00994	CbGpPWpGaD
Labetalol—ADRB2—Arf6 trafficking events—CTNNB1—adrenal gland cancer	6.94e-05	0.00991	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—GNRHR—adrenal gland cancer	6.87e-05	0.00981	CbGpPWpGaD
Labetalol—ADRB1—G alpha (s) signalling events—GNAS—adrenal gland cancer	6.8e-05	0.0097	CbGpPWpGaD
Labetalol—ADRB2—G alpha (s) signalling events—GNAS—adrenal gland cancer	6.65e-05	0.00949	CbGpPWpGaD
Labetalol—ADRB1—Class A/1 (Rhodopsin-like receptors)—GNRH1—adrenal gland cancer	6.25e-05	0.00892	CbGpPWpGaD
Labetalol—ADRB2—Class A/1 (Rhodopsin-like receptors)—GNRH1—adrenal gland cancer	6.11e-05	0.00873	CbGpPWpGaD
Labetalol—ADRB1—Calcium Regulation in the Cardiac Cell—GNAS—adrenal gland cancer	5.87e-05	0.00838	CbGpPWpGaD
Labetalol—ADRB2—Calcium Regulation in the Cardiac Cell—GNAS—adrenal gland cancer	5.74e-05	0.00819	CbGpPWpGaD
Labetalol—ADRB1—Class A/1 (Rhodopsin-like receptors)—TSHR—adrenal gland cancer	5.57e-05	0.00795	CbGpPWpGaD
Labetalol—ADRB2—Class A/1 (Rhodopsin-like receptors)—TSHR—adrenal gland cancer	5.45e-05	0.00778	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—GNRH1—adrenal gland cancer	4.76e-05	0.00679	CbGpPWpGaD
Labetalol—ADRB2—GPCR ligand binding—GNRH1—adrenal gland cancer	4.66e-05	0.00665	CbGpPWpGaD
Labetalol—ADRB1—G alpha (s) signalling events—POMC—adrenal gland cancer	4.58e-05	0.00653	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—GNRH1—adrenal gland cancer	4.53e-05	0.00647	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—GNRHR—adrenal gland cancer	4.49e-05	0.00641	CbGpPWpGaD
Labetalol—ADRB2—G alpha (s) signalling events—POMC—adrenal gland cancer	4.48e-05	0.00639	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—GNRHR—adrenal gland cancer	4.39e-05	0.00627	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—TSHR—adrenal gland cancer	4.24e-05	0.00606	CbGpPWpGaD
Labetalol—ADRB3—GPCR ligand binding—GNAS—adrenal gland cancer	4.16e-05	0.00593	CbGpPWpGaD
Labetalol—ADRB2—GPCR ligand binding—TSHR—adrenal gland cancer	4.15e-05	0.00592	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—GNRH1—adrenal gland cancer	4.12e-05	0.00587	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—GNRHR—adrenal gland cancer	4.08e-05	0.00582	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—GNRHR—adrenal gland cancer	4.06e-05	0.00579	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—TSHR—adrenal gland cancer	4.04e-05	0.00577	CbGpPWpGaD
Labetalol—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—adrenal gland cancer	4.01e-05	0.00572	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—GNRHR—adrenal gland cancer	3.99e-05	0.00569	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—SH3KBP1—adrenal gland cancer	3.77e-05	0.00538	CbGpPWpGaD
Labetalol—ADRB3—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	3.68e-05	0.00525	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—TSHR—adrenal gland cancer	3.67e-05	0.00524	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—ZNRF3—adrenal gland cancer	3.55e-05	0.00506	CbGpPWpGaD
Labetalol—CYP2D6—Phase 1 - Functionalization of compounds—POMC—adrenal gland cancer	3.25e-05	0.00464	CbGpPWpGaD
Labetalol—ADRB3—GPCR ligand binding—POMC—adrenal gland cancer	2.8e-05	0.004	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—GNRH1—adrenal gland cancer	2.69e-05	0.00384	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—PRKACA—adrenal gland cancer	2.63e-05	0.00376	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—GNRH1—adrenal gland cancer	2.63e-05	0.00376	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—GNAS—adrenal gland cancer	2.47e-05	0.00352	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—CDC42—adrenal gland cancer	2.46e-05	0.00351	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—GNRH1—adrenal gland cancer	2.44e-05	0.00349	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—GNRH1—adrenal gland cancer	2.43e-05	0.00347	CbGpPWpGaD
Labetalol—ADRB2—GPCR ligand binding—GNAS—adrenal gland cancer	2.41e-05	0.00345	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—GNRHR—adrenal gland cancer	2.41e-05	0.00344	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—TSHR—adrenal gland cancer	2.4e-05	0.00342	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—GNRH1—adrenal gland cancer	2.39e-05	0.00341	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—GNRHR—adrenal gland cancer	2.36e-05	0.00336	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—GNAS—adrenal gland cancer	2.35e-05	0.00335	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—TSHR—adrenal gland cancer	2.35e-05	0.00335	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—SH3KBP1—adrenal gland cancer	2.24e-05	0.0032	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—CDC42—adrenal gland cancer	2.23e-05	0.00319	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—SPRY2—adrenal gland cancer	2.22e-05	0.00317	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—SH3KBP1—adrenal gland cancer	2.19e-05	0.00313	CbGpPWpGaD
Labetalol—ADRB1—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	2.18e-05	0.00311	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—TSHR—adrenal gland cancer	2.18e-05	0.00311	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—TSHR—adrenal gland cancer	2.17e-05	0.00309	CbGpPWpGaD
Labetalol—ADRB2—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	2.13e-05	0.00305	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—GNAS—adrenal gland cancer	2.13e-05	0.00305	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—TSHR—adrenal gland cancer	2.13e-05	0.00304	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—ZNRF3—adrenal gland cancer	2.11e-05	0.003	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—ZNRF3—adrenal gland cancer	2.06e-05	0.00294	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—MEN1—adrenal gland cancer	2.04e-05	0.00291	CbGpPWpGaD
Labetalol—CYP2D6—Biological oxidations—POMC—adrenal gland cancer	1.73e-05	0.00246	CbGpPWpGaD
Labetalol—ADRB1—GPCR ligand binding—POMC—adrenal gland cancer	1.66e-05	0.00237	CbGpPWpGaD
Labetalol—ADRB2—GPCR ligand binding—POMC—adrenal gland cancer	1.63e-05	0.00232	CbGpPWpGaD
Labetalol—ADRB3—GPCR downstream signaling—POMC—adrenal gland cancer	1.58e-05	0.00226	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—PRKACA—adrenal gland cancer	1.56e-05	0.00223	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—PRKACA—adrenal gland cancer	1.56e-05	0.00222	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—SDHB—adrenal gland cancer	1.54e-05	0.0022	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—PRKACA—adrenal gland cancer	1.53e-05	0.00218	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—CDC42—adrenal gland cancer	1.46e-05	0.00208	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—GNRH1—adrenal gland cancer	1.44e-05	0.00206	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—POMC—adrenal gland cancer	1.44e-05	0.00205	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—CDC42—adrenal gland cancer	1.43e-05	0.00204	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—GNRH1—adrenal gland cancer	1.41e-05	0.00201	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—GNAS—adrenal gland cancer	1.39e-05	0.00199	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—GNAS—adrenal gland cancer	1.36e-05	0.00195	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—CDC42—adrenal gland cancer	1.33e-05	0.00189	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—SPRY2—adrenal gland cancer	1.32e-05	0.00188	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CDC42—adrenal gland cancer	1.32e-05	0.00188	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—CDC42—adrenal gland cancer	1.3e-05	0.00185	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—SPRY2—adrenal gland cancer	1.29e-05	0.00184	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—TSHR—adrenal gland cancer	1.29e-05	0.00184	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—IGF2—adrenal gland cancer	1.27e-05	0.00181	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—GNAS—adrenal gland cancer	1.27e-05	0.00181	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—GNAS—adrenal gland cancer	1.26e-05	0.0018	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—TSHR—adrenal gland cancer	1.26e-05	0.0018	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—GNAS—adrenal gland cancer	1.24e-05	0.00177	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—IGF1R—adrenal gland cancer	1.23e-05	0.00175	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—MEN1—adrenal gland cancer	1.21e-05	0.00173	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—MEN1—adrenal gland cancer	1.18e-05	0.00169	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—TERT—adrenal gland cancer	1.06e-05	0.00151	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—RRM1—adrenal gland cancer	9.94e-06	0.00142	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—SDHD—adrenal gland cancer	9.94e-06	0.00142	CbGpPWpGaD
Labetalol—ADRB1—GPCR downstream signaling—POMC—adrenal gland cancer	9.39e-06	0.00134	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—PRKACA—adrenal gland cancer	9.23e-06	0.00132	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—BAD—adrenal gland cancer	9.21e-06	0.00131	CbGpPWpGaD
Labetalol—ADRB2—GPCR downstream signaling—POMC—adrenal gland cancer	9.19e-06	0.00131	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—PRKACA—adrenal gland cancer	9.03e-06	0.00129	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—POMC—adrenal gland cancer	8.53e-06	0.00122	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—POMC—adrenal gland cancer	8.49e-06	0.00121	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—BRAF—adrenal gland cancer	8.38e-06	0.0012	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—POMC—adrenal gland cancer	8.34e-06	0.00119	CbGpPWpGaD
Labetalol—ADRB3—Signaling by GPCR—EGFR—adrenal gland cancer	8.12e-06	0.00116	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CDC42—adrenal gland cancer	7.83e-06	0.00112	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CDC42—adrenal gland cancer	7.66e-06	0.00109	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—IGF2—adrenal gland cancer	7.55e-06	0.00108	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—GNAS—adrenal gland cancer	7.48e-06	0.00107	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—MED12—adrenal gland cancer	7.41e-06	0.00106	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—IGF2—adrenal gland cancer	7.38e-06	0.00105	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—GNAS—adrenal gland cancer	7.32e-06	0.00104	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—IGF1R—adrenal gland cancer	7.3e-06	0.00104	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—IGF1R—adrenal gland cancer	7.14e-06	0.00102	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—TERT—adrenal gland cancer	6.28e-06	0.000896	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—TERT—adrenal gland cancer	6.14e-06	0.000877	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—CTNNB1—adrenal gland cancer	6.06e-06	0.000864	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—BAD—adrenal gland cancer	5.46e-06	0.00078	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PRKACA—adrenal gland cancer	5.41e-06	0.000772	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—BAD—adrenal gland cancer	5.35e-06	0.000763	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—POMC—adrenal gland cancer	5.04e-06	0.000719	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—BRAF—adrenal gland cancer	4.97e-06	0.00071	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—POMC—adrenal gland cancer	4.93e-06	0.000703	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—BRAF—adrenal gland cancer	4.87e-06	0.000694	CbGpPWpGaD
Labetalol—ADRB1—Signaling by GPCR—EGFR—adrenal gland cancer	4.82e-06	0.000688	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—EGFR—adrenal gland cancer	4.8e-06	0.000685	CbGpPWpGaD
Labetalol—ADRB2—Signaling by GPCR—EGFR—adrenal gland cancer	4.72e-06	0.000673	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—GNAS—adrenal gland cancer	4.38e-06	0.000626	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—ABCB1—adrenal gland cancer	4.3e-06	0.000614	CbGpPWpGaD
Labetalol—ADRB3—Signaling Pathways—TP53—adrenal gland cancer	4.03e-06	0.000575	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—CTNNB1—adrenal gland cancer	3.59e-06	0.000513	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—CTNNB1—adrenal gland cancer	3.52e-06	0.000502	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—POMC—adrenal gland cancer	2.95e-06	0.000421	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—EGFR—adrenal gland cancer	2.85e-06	0.000407	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—EGFR—adrenal gland cancer	2.79e-06	0.000398	CbGpPWpGaD
Labetalol—ADRB1—Signaling Pathways—TP53—adrenal gland cancer	2.39e-06	0.000341	CbGpPWpGaD
Labetalol—CYP2D6—Metabolism—PTGS2—adrenal gland cancer	2.35e-06	0.000336	CbGpPWpGaD
Labetalol—ADRB2—Signaling Pathways—TP53—adrenal gland cancer	2.34e-06	0.000334	CbGpPWpGaD
